Partner Channels: Auto | Bill Pay | IT Education | Jobs | Lifestyle | Technology | Travel
May 12, 2001
|
|
|
|
|
|
||
|
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Wedding | Women Partner Channels: Auto | Bill Pay | IT Education | Jobs | Lifestyle | Technology | Travel |
||
|
|
||
|
Home >
Money > Business Headlines > Report May 12, 2001 |
Feedback
|
|
|
Cadila unveils anti-AIDS kitBS Corporate Bureau Ahmedabad-based Cadila Pharmaceuticals Ltd on Friday launched an HIV (AIDS) detection kit, which it claimed was the fastest such detection kit available in the world, and priced it below Rs 2,000. The kit is being made available for use immediately through the diagnostics division of Casil Health Products Ltd, the hospital products company of Cadila group, Cadila Pharma chairman I A Mody said in New Delhi. The kit can detect HIV in three minutes (each test costing Rs 39), the company claimed, making it faster and cheaper than other rapid kit which usually detects the presence of the AIDS-causing virus in around 30 minutes. However, Mody clarified that though HIV can be detected by the kit, a positive case will be confirmed only after a subsequent Elisa test. He said the company was also in the process of launching a cheaper Elisa kit. In the domestic market for AIDS diagnostic kits - which Mody claimed was around Rs 500 million - the Rs 4-billion Cadila is targeting a 40 per cent share. According to him, the market is expected to grow four-times within the next two years. Cadila is also looking at the exports market. The company is all set to launch the 'Neva HIV detection kit' in the South African market, where domestic firm Cipla recently launched cheap anti-AIDS drugs causing ripples in the world drug industry. "We are in the process of getting necessary regulatory approvals. The first consignment should be shipped by the year-end," Mody said. The product will also be exported to South-East Asia, Europe, Latin America and other African countries. The Neva kit has been developed in collaboration with the University of Delhi and the Department of Biotechnology, government of India. Cadila has also sought certification from the US Food and Drug Administration and the UK medicine control agency for its manufacturing facility. The company is also in talks with a Japanese firm for a possible tie-up for marketing and research and development. Mody said the company had about 40 products in the pipeline and will consider a listing on the domestic as well as overseas bourses by 2003. "But it is too early to talk about it," he added. Powered by YOU MAY ALSO WANT TO READ:
|
||||
